論文

国際誌
2020年12月

Disproportionally Impaired Diffusion Capacity Relative to Airflow Limitation in COPD.

COPD
  • Naoya Tanabe
  • ,
  • Chin Kook Rhee
  • ,
  • Susumu Sato
  • ,
  • Shigeo Muro
  • ,
  • Hiroshi Shima
  • ,
  • Kazuya Tanimura
  • ,
  • Ki-Suck Jung
  • ,
  • Kwang Ha Yoo
  • ,
  • Toyohiro Hirai

17
6
開始ページ
627
終了ページ
634
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1080/15412555.2020.1845639

Forced expiratory volume in 1 s (FEV1) is a standard physiological index of chronic obstructive pulmonary disease (COPD), but reflects emphysema and vascular abnormalities less sensitively than diffusion capacity for carbon monoxide (DLCO). This study tested whether a disproportionally impaired DLCO relative to FEV1 (FEV1z-score>-3 and DLCOz-score≤-3) is a common functional COPD phenotype associated with distinct clinical and structural features and the prognosis of two cohorts. The cross-sectional analyses of the Korea COPD Subgroup Study (KOCOSS) cohort (multicenter study in Korea) included 743 males with COPD whose DLCO was available. The cross-sectional and longitudinal analyses of the Kyoto University Cohort (single-center study in Japan) included 195 males with COPD who were prospectively followed for 10 years. A disproportionally impaired DLCO relative to FEV1 was observed in 29% and 31% of patients in the KOCOSS and Kyoto University cohorts, respectively. In the multivariable analysis, the disproportionally impaired DLCO was associated with worse symptoms, shorter 6-minute walking distance, paraseptal and centrilobular emphysema on computed tomography, and reduced arterial oxygen and carbon dioxide pressures compared to the reference (FEV1z-score>-3 and DLCOz-score>-3). In the multivariable Cox proportional hazard model, a higher long-term mortality was observed in the disproportionally impaired DLCO group than in the reference group (hazard ratio [95% confidence interval] = 3.09 [1.52-6.29]) and similar to the DLCOz-score≤-3 and FEV1z-score≤-3 group. The disproportionally impaired DLCO relative to FEV1 is common and associated with increased symptoms, emphysema, arterial blood gas abnormalities, and increased long-term mortality in patients with COPD.

リンク情報
DOI
https://doi.org/10.1080/15412555.2020.1845639
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/33222554
ID情報
  • DOI : 10.1080/15412555.2020.1845639
  • PubMed ID : 33222554

エクスポート
BibTeX RIS